Intellia Therapeutics Inc (NASDAQ:NTLA)
| 88.12 Delayed Data As of Jun 14 |  +2.71 / +3.18%Today’s Change | 16.54 Today|||52-Week Range 92.00 | +61.99% Year-to-Date |
Latest NTLA News | Press Releases
| CRISPR (CRSP) Up on Positive New Gene Therapy CTX001 Data Jun 14 / Zacks.com - Paid Partner Content | What's the Best Way to Invest in Genetics Stocks? Jun 07 / MotleyFool.com - Paid Partner Content |
| 3 Biotech ETFs That Could Double Your Money by 2025 With Zero Effort Jun 13 / MotleyFool.com - Paid Partner Content | This Genetics Stock Could Have a Bright Future Jun 03 / MotleyFool.com - Paid Partner Content |
Today’s Trading
| Previous close | 85.29 |
| Today’s open | 84.21 |
| Day’s range | 84.21 - 89.26 |
| Volume | 1,740,890 |
| Average volume (3 months) | 1,339,117 |
| Market cap | $5.8B |
Data as of 4:00pm ET, 06/14/2021
Growth & Valuation
| Earnings growth (last year) | -13.81% |
| Earnings growth (this year) | -9.14% |
| Earnings growth (next 5 years) | +7.00% |
| Revenue growth (last year) | +34.55% |
| P/E ratio | NM |
| Price/Sales | 52.52 |
| Price/Book | 10.72 |
Competitors
Data as of 3:59pm ET, 06/14/2021
Financials
| Next reporting date | August 5, 2021 |
| EPS forecast (this quarter) | -$0.62 |
| Annual revenue (last year) | $58.0M |
| Annual profit (last year) | -$134.2M |
| Net profit margin | -231.46% |
Profile
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters Cambridge, Massachusetts |
Forecasts
